Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Aim(s): The main objective was to evaluate Rb expression by immunohistochemistry (IHC) as a predictive and/or prognostic factor in patients with G3 NEC. Secondary objectives were to evaluate predictive factors of response, progression-free (PFS) and overall survival (OS) under first line platinum/etoposide (PE).
Materials and methods: Inclusion criteria were: G3NEC whatever the primary and stage, first line treatment with PE and available tumor samples. G3NET were excluded. We report monocentric data from 63 evaluable metastatic patients (pts).
Conference: 17th Annual ENETS Conference 2020 (2020)
Presenting Author: Dr Julien Hadoux
, Kanaan C
, Planchard D
, Malka D
, Ducreux M
, Pautier P
, Loriot Y
, Duvillard P
, Al Ghuzlan A
, Scoazec J Y
, Baudin E
To read results and conclusion, please login ...
Further abstracts you may be interested in